Agios Pharmaceuticals (AGIO) Stock Forecast, Price & News

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Agios Pharmaceuticals in the last twelve months. There are currently 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" AGIO shares.
View AGIO analyst ratings or view top-rated stocks.

4 Wall Street analysts have issued 1 year price targets for Agios Pharmaceuticals' shares. Their AGIO share price forecasts range from $32.00 to $41.00. On average, they anticipate the company's stock price to reach $36.00 in the next year. This suggests a possible upside of 46.8% from the stock's current price.
View analysts price targets for AGIO or view top-rated stocks among Wall Street analysts.

Agios Pharmaceuticals' stock was trading at $28.08 at the beginning of the year. Since then, AGIO shares have decreased by 12.6% and is now trading at $24.53.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023.
View our AGIO earnings forecast.

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) announced its quarterly earnings data on Thursday, August, 3rd. The biopharmaceutical company reported ($1.51) earnings per share for the quarter, beating analysts' consensus estimates of ($1.60) by $0.09. The biopharmaceutical company had revenue of $6.70 million for the quarter, compared to the consensus estimate of $6.46 million. Agios Pharmaceuticals had a negative net margin of 1,042.56% and a negative trailing twelve-month return on equity of 20.24%. The business's quarterly revenue was up 20.1% compared to the same quarter last year. During the same quarter last year, the firm earned ($1.68) earnings per share.

ETFs with the largest weight of Agios Pharmaceuticals (NASDAQ:AGIO) stock in their portfolio include First Trust NYSE Arca Biotechnology Index Fund (FBT), Virtus LifeSci Biotech Products ETF (BBP), WisdomTree BioRevolution Fund (WDNA) and ALPS Medical Breakthroughs ETF (SBIO).Simplify Propel Opportunities ETF (SURI).

11 employees have rated Agios Pharmaceuticals Chief Executive Officer Jackie Fouse on Glassdoor.com. Jackie Fouse has an approval rating of 100% among the company's employees. This puts Jackie Fouse in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Agios Pharmaceuticals investors own include Gilead Sciences (GILD), Micron Technology (MU), Alibaba Group (BABA), bluebird bio (BLUE), Pfizer (PFE), Vertex Pharmaceuticals (VRTX), NVIDIA (NVDA), Tesla (TSLA) and Netflix (NFLX).

Agios Pharmaceuticals trades on the NASDAQ under the ticker symbol "AGIO."

Agios Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (8.48%), Rock Springs Capital Management LP (4.82%), State Street Corp (4.63%), JPMorgan Chase & Co. (4.47%), Dimensional Fund Advisors LP (4.06%) and ArrowMark Colorado Holdings LLC (2.82%). Insiders that own company stock include Brian Goff, Carman Alenson, Cecilia Jones, Christopher Bowden, Darrin Miles, David P Schenkein, Jacqualyn A Fouse, James William Burns, Kaye I Foster-Cheek and Theodore James Jr Washburn.
View institutional ownership trends.

Shares of AGIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of AGIO stock can currently be purchased for approximately $24.53.

Agios Pharmaceuticals (NASDAQ:AGIO) has a market capitalization of $1.37 billion and generates $14.24 million in revenue each year. The biopharmaceutical company earns $-231,800,000.00 in net income (profit) each year or ($3.80) on an earnings per share basis.

The company employs 389 workers across the globe.

Agios Pharmaceuticals' mailing address is 88 SIDNEY STREET, CAMBRIDGE MA, 02139. The official website for the company is www.agios.com. The biopharmaceutical company can be reached via phone at (617) 649-8600 or via email at investors@agios.com.